We have previously reported that the Jak2 tyrosine kinase but not Jak1 is tyrosine phosphorylated in the absence of IL-3 in Bcr ± Abl positive M3.16 cells, which are rendered IL-3 independent by BCR ± ABL gene expression. We have explored the involvement of Jak2 tyrosine phosphorylation in Bcr-Abl oncogenic eects. Our results indicate that Jak2 became tyrosine-phosphorylated in a number of cell lines expressing Bcr ± Abl, when maintained in medium lacking IL-3, whereas Bcr ± Abl negative cells lacked Jak2 tyrosine phosphorylation. Jak2 was poorly tyrosine-phosphorylated in cells expressing the SH2 deletion mutant of Bcr ± Abl compared to either wild-type Bcr ± Abl or its SH3 deletion mutant. Moreover, tyrosine phosphorylation of Jak2 by Bcr ± Abl was inhibited by the Abl tyrosine kinase inhibitor, STI 571, in a dose-dependent manner. This inhibition of Bcr ± Abl kinase by the drug did not interfere with the ability of Jak2 and Bcr ± Abl to form a complex. Studies with deletion mutants of Bcr ± Abl indicated that the Cterminal domain of Abl within Bcr ± Abl was involved in complex formation with Jak2. Similarly, GST ± Abl pulldown assays con®rmed the strong binding to Jak2 by the C-terminus of Abl. Jak2 peptide substrate studies indicated that the Bcr ± Abl and Abl tyrosine kinases speci®cally phosphorylated Y1007 of Jak2 but only poorly phosphorylated Y1008. Phosphorylation of Y1007 of Jak2 is known to be critical for its tyrosine kinase activation. Tyrosine residue 1007 of Jak2 was phosphorylated in 32Dp210 cells as measured by Western blotting with a phosphotyrosine 1007 sequence-speci®c antibody. A kinase-inactive Jak2 mutant blocked the colony forming ability of K562 cells. Tumor formation of K562 cells in nude mice was similarly inhibited by this kinase-inactive Jak2 mutant. This inhibition was independent of Stat5 tyrosine phosphorylation. Furthermore, tyrosine-phosphorylated Jak2 was detected in blood cells from CML patients in blast crisis but not in a normal marrow sample. In summary, these ®ndings provide strong evidence that the Jak2 tyrosine kinase is a critical factor in Bcr ± Abl malignant transformation. Oncogene (2001) 20, 6188 ± 6195.
Introduction
The Jak2 kinase is a member of the Janus kinase family, which is involved in signal transduction of cytokine growth factors (Ward et al., 2000) . Jak2 is known to be activated by autophosphorylation of tyrosine 1007, which is induced by binding cytokines, such as IL-3, to their receptors (Feng et al., 1997) . Jak2 as a result of its activation phosphorylates the common beta chain of the IL-3 receptor causing the recruitment of Stat5 to the Jak2/cytokine receptor complex. Subsequent tyrosine phosphorylation of Stat5 stimulates its dimerization and rapid translocation of Stat5 to the nucleus (Darnell et al., 1994) . Knockout mice studies have established that Jak2 is required for normal hematopoiesis (Parganas et al., 1998; Neubauer et al., 1998) .
Bcr ± Abl as a result of its activated tyrosine kinase activity is known to phosphorylate a number of cellular targets (Sawyers, 1999) . These include tyrosine (Y) 177 within the cis BCR sequence of Bcr ± Abl which is involved in the binding of the SH2/SH3-containing adaptor protein, Grb2, and subsequent activation of the Ras pathway (Pendergast et al., 1993; Puil et al., 1994) . A second key phosphorylation target is the Shc protein, which is also involved in Ras activation (Puil et al., 1994 ). Yet another SH2/SH3-containing adaptor protein, Crkl, is phosphorylated by Bcr ± Abl but its role is as yet not clearly de®ned (ten Hoeve et al., 1994) . Another prominent Bcr ± Abl target is the Stat5 protein. Tyrosine phosphorylation of Stat5 activates Stat5 translocation to the nucleus and subsequent DNA binding to known Stat5 binding sites (Carlesso et al., 1996; Shuai et al., 1996) .
We and others have shown that Jak2 is tyrosinephosphorylated in cells rendered cytokine-independent by Bcr ± Abl expression (Wilson-Rawls et al., 1996; Ilaria and Van Etten, 1996; Chai et al., 1997) . We have further shown that Jak1 is not tyrosine-phosphorylated in such cells, indicating that Bcr ± Abl is speci®cally targeting the Jak2 kinase (Wilson-Rawls et al., 1996) . Also, Stat5 activation is required for Bcr ± Abl induced survival of P210 expressing hematopoietic cells (Horita et al., 2000; Nieborowska-Skorska et al., 1999; Sillaber et al., 2000) . Because Bcr ± Abl is known to directly phosphorylate Stat5, it is widely believed that tyrosine phosphorylation of Jak2 is irrelevant for Bcr ± Abl induced leukemia eects (Carlesso et al., 1996) .
In this report, we show that Bcr ± Abl forms a complex with Jak2, and induces tyrosine phosphorylation of Jak2; full phosphorylation requires the SH2 domain of Bcr ± Abl. We found that Y1007 of Jak2 was phosphorylated in Bcr ± Abl positive cells; phosphorylation of Jak2 Y1007 is known to be required for Jak2 kinase activation. Importantly, a kinase-inactive form of Jak2 transfected into the K562 leukemia cell line interfered with the oncogenic eects of Bcr ± Abl.
Results
Jak2 is tyrosine phosphorylated in Bcr ± Abl positive cell lines and CML patient cells
Our previous studies showed that Jak2 was tyrosine phosphorylated in the absence of IL-3 in M3.16 cells (Wilson-Rawls et al., 1996) , a cell clone derived from a pool of BCR ± ABL expressing IL-3 dependent Mo7e cells. To determine whether Jak2 was similarly phosphorylated in other Bcr ± Abl positive cell lines, we performed phosphotyrosine Western blotting on Jak2 immunoprecipitates obtained from cell lysates derived from several Bcr ± Abl positive cell lines ( Figure  1a ). HL60 cells lacked tyrosine phosphorylated Jak2 whereas HL60 cells expressing P185 BCR ± ABL contained tyrosine phosphorylated Jak2. 32D cells expressing P210 BCR ± ABL also contained tyrosine phosphorylated Jak2 (Figure 1a) . Similarly, K562 expressing (P210 BCR ± ABL) and B15 expressing cells (P185 BCR ± ABL) cells also expressed tyrosine phosphorylated Jak2 (Figure 1a) . The Jak2 immunoprecipitates contained similar levels of Jak2 in all of these cell lines (Figure 1b) . Notably, K562 cells had the highest levels of Jak2 tyrosine phosphorylation of the cell lines examined. These results showed that Jak2 was routinely tyrosine-phosphorylated in Bcr ± Abl positive cell lines.
We also performed experiments with uncultured CML cells from blast crisis patients to determine whether Jak2 was tyrosine-phosphorylated. In three samples of CML patient cells, Jak2 was detected with the Jak2 antibody, and this protein was tyrosinephosphorylated ( Figure 1c) . One normal control, although expressing Jak2, was not detectably tyrosine phosphorylated on Jak2 (Figure 1d ). These results suggest that Bcr ± Abl is activating Jak2 in primary cells from patients with CML.
The SH2 domain of Bcr ± Abl is required for efficient phosphorylation of Jak2
It is known that the SH2 domain is involved in selecting targets of non-receptor tyrosine kinases (Songyang et al., 1995) . Therefore, we compared the ability of 32D cells expressing either wild-type Bcr ± Abl or its SH2 deletion mutant to induce tyrosine phosphorylation of Jak2 (Figure 2 ). Several experiments were performed and the results indicated that the P210 BCR ± ABL mutant lacking the SH2 domain was de®cient in its ability to phosphorylate Jak2 whereas the SH3 deletion mutant was only slightly decreased in its ability to phosphorylate Jak2. Jak2 tyrosine phosphorylation by Bcr ± Abl is dependent on the tyrosine kinase activity of Bcr ± Abl
To provide further evidence that tyrosine phosphorylation of Jak2 is induced by Bcr ± Abl, we performed experiments with STI-571 (an inhibitor of the Bcr ± Abl tyrosine kinase) to determine whether it interfered with the tyrosine phosphorylation of Jak2. In these studies we incubated 32D cells expressing P210 BCR ± ABL with various concentrations of STI-571 at levels known to inhibit the Bcr ± Abl tyrosine kinase (Druker et al., 1996) (Figure 3 ). In these experiments we harvested Jak2 immunoprecipitates from lysates of 32D cells expressing P210 BCR ± ABL, and performed Western blotting with anti-phosphotyrosine (4G10), anti-Jak2 and anti-Abl (8E9). STI-571 was added to cells 3 h prior to immunoprecipitation. The results showed that Jak2 antibody immunoprecipitated Jak2 and coprecipitated P210 BCR-ABL (Figure 3b,c) . However, co-precipitation of c-Abl with Jak2 was not detected in such lysates even though the total lysate detected the cAbl protein using the anti-Abl 8E9 antibody (not shown). Importantly, tyrosine phosphorylation of both P210 BCR ± ABL and Jak2 was inhibited in a dosedependent manner by STI-571 (Figure 3a) . Of interest, (Liu et al., 1993) containing 1 mg/ml of AEBSF from CML blast crisis patients or mononuclear cells from normal donor bone marrow. Jak2 was immunoprecipitated with anti-Jak2 antibody, SC-294AC, and immunoblotted with anti-phosphotyrosine antibody, 4G10. (d) The above membrane was stripped and immunoblotted with antiJak2 antibody, SC-278 the concentration of STI-571 required to inhibit tyrosine phosphorylation of P210 was similar to that required to inhibit Jak2 tyrosine phosphorylation ( Figure 3d ). As controls, we showed that STI-571 did not inhibit tyrosine phosphorylation of Jak2 induced by IL-3 in 32D cells lacking Bcr ± Abl expression ( Figure 3 , right lanes). These results indicate that Bcr ± Abl is critically involved in tyrosine phosphorylation of Jak2. Of interest at concentrations of STI-571 that almost completely inhibited the tyrosine kinase of Bcr ± Abl, Jak2 and Bcr ± Abl maintained their ability to form complexes (Figure 3b ,c, the 10 mM lane).
A number of experiments like the one shown in Figure 3 demonstrated that Bcr ± Abl and Jak2 readily form complexes independent of Jak2 and Abl kinase activities. For example in COS1 cells co-transfected with kinase-active or -inactive Jak2 and kinase-active or -inactive c-Abl, we found Jak2 and c-Abl proteins, no matter whether they were kinase-active or -inactive, formed complexes (results not shown). These results indicate that the kinase activities of Jak2 and Abl are not involved in forming complexes with each other.
Jak2 strongly binds to the C-terminus of Bcr ± Abl
We explored the region of Bcr ± Abl that bound to Jak2. Previous studies with v-Abl and Jak1 indicated that the C-terminus of v-Abl bound to Jak1 (Danial et al., 1998) . In our studies we examined two types of deletion mutant Bcr ± Abl constructs with respect to binding to Jak2 (Figure 4 ). In these experiments we cotransfected various deletion mutant constructs of Bcr ± Abl with Jak2 in COS1 cells. Jak2 antibody was used to harvest both Jak2 and those forms of Bcr ± Abl that bound to Jak2. The results showed that a Bcr ± Abl construct lacking the C-terminal domain was only poorly bound to Jak2 (Figure 4b , lane 1) whereas the construct containing the amino terminal portion of Bcr joined to the C-terminal domain of Abl bound strongly to Jak2 (Figure 4b , lane 2).
To con®rm these ®ndings, we tested the ability of various GST ± Abl fragments to interact with Jak2 ( Figure 5 ). Figure 5a shows a diagram of the various GST ± Abl protein fragments. Cell lysates from Sf9 cells co-expressing Jak2 and recombinant GST ± Abl fusion proteins were processed by incubation with GSH-agarose beads in pull-down assays. The results showed that the distal portion of Cterminal segment of Abl was bound strongly to Jak2 (Figure 5b , CT4 lane). Thus, the C-terminal Abl sequences within Bcr ± Abl represent the minimum required binding site that is involved in forming a complex with Jak2.
Y1007 of Jak2 is the target of Bcr ± Abl tyrosine phosphorylation
It is established that Y1007 of Jak2 is a key site of phosphorylation required for activation of the Jak2 kinase (Feng et al., 1997) . To determine whether Bcr ± Abl and Abl can phosphorylate this residue, we synthesized several Jak2 peptides containing Y1007. Of interest, a second tyrosine (Y1008) is located next to Y1007. We prepared four such peptides (Figure 6a ): the wild-type sequence containing Y1007 and Y1008; and three mutant peptides that were substituted with either F at Y1007 (Y1007F) or with F at Y1008 (Y1008F) or the double mutant (Y1007F/Y1008F). These peptides were used as targets for either the commercially available 45 kDa Abl kinase (Figure 6a, upper panel) or the Bcr ± Abl kinase (as an anti-Abl P6D immunoprecipitate) (Figure 6a, lower panel) . The results showed that both wild-type and Y1007/F1008 peptides were strongly phosphorylated by both Abl and Bcr ± Abl tyrosine kinases. However, the Y1007F mutant was only poorly phosphorylated whereas the double F mutant was not detectably phosphorylated by either kinase. These results suggest that Y1007 is a site for phosphorylation by the activated Abl kinase.
To determine whether Y1007 residue of Jak2 becomes phosphorylated within 32D cells expressing both Jak2 and Bcr-Abl, we immunoprecipitated Jak2 from P210 32D cells and performed Western blots with a sequence-speci®c phosphotyrosine 1007 rabbit antiserum (Figure 6b ). In these experiments we pretreated the rabbit serum with excess unphosphorylated Jak2 peptide to remove reactivity of the antibody with nonphosphorylated protein (Figure 6b, upper panel) . Pretreatment of the antiserum with excess phosphotyrosine 1007 peptide prevented detection of the Jak2 protein (Figure 6b , middle panel). Western blots with anti-Jak2 antibody veri®ed that similar levels of Jak2 were present in each immunoprecipitate (Figure 6b , lower panel). Jak2 phosphorylated at the Y1007 residue was not seen in 32D cells lacking Bcr ± Abl Figure 5 The C-terminal domain of Abl binds to Jak2. (a) Diagram of the Bcr ± Abl oncogene product and the various GST ± Abl fusion proteins used in the binding assay. (b) Jak2 was co-expressed with each of the GST-Abl fusion proteins shown in a or with GST alone as a negative control in Sf-9 insect cells. The GST fusion proteins were precipitated from cell lysates with glutathione-agarose beads, and bound Jak2 was visualized by immunoblotting (Bound). The levels of the GST fusion proteins were determined by immunoblotting an aliquot of the precipitate with an anti-GST antibody (GST). The asterisks indicate the positions of the full-length fusion proteins. Expression of Jak2 in each sample was veri®ed by blotting aliquots of the cell lysates with the anti-Jak2 antibody (Lysate). The arrows indicate the position of Jak2. This experiment was repeated four times with comparable results Figure 6b, upper panel) . These results showed that Jak2 was speci®cally detected by Jak2 phosphotyrosine 1007 sequence-speci®c antiserum in Bcr ± Abl positive cells, indicating that Bcr ± Abl can activate the tyrosine kinase of Jak2.
Oncogene
Effects of kinase-inactive Jak2 on tumor formation activity of K562 leukemia cells
To determine whether Jak2 is required for tumor formation induced by Bcr ± Abl positive K562 cells, we generated a number of cell clones containing a stablytransfected kinase-inactive JAK2 gene (Feng et al., 1997) . Several clones were obtained that expressed varying levels of kinase-inactive Jak2. K562 clones K1-4 and K1-8, which had similar levels of endogenous and kinase-inactive Jak2, were tested for their ability to form colonies in soft agar in comparison to the vector transfected control (Figure 7a ) during a 2 week period. These kinase-inactive Jak2 expressing cell clones, despite growing well in liquid cultures, had sharply reduced colony-forming ability compared to the vector control.
These clones were also tested for their ability to form solid tumors in nude mice. Both clones had reduced ability to form tumors compared to the vector control (Figure 7b) . Similar results were obtained with several other clones (not shown). Moreover, a mixture of seven clones was severely inhibited in tumor-forming ability compared to the vector control (not shown). These results indicate that the kinase-inactive Jak2 functioned in cells as a dominant-negative Jak2 molecule.
Kinase-inactive Jak2 does not reduce tyrosine phosphorylation of Stat5
Because the Jak-Stat signaling pathway is a major pathway for survival and growth of hematopoietic cells (Ward et al., 2000) , we determined whether K562 cell clones expressing kinase-inactive Jak2 had decreased levels of Stat5 tyrosine phosphorylation. We examined two such K562 cell clones that interfered with growth of tumors and found that the level of tyrosine phosphorylated Stat5 was not signi®cantly eected (Figure 8) . Thus, the decrease in tumor-growth observed in the nude mice experiments as a result of expression of a kinase-inactive Jak2 was not due to decreased activation of Stat5.
Discussion
Our ®ndings indicate that Jak2 plays an important role in transmitting the oncogenic signal induced by the activated tyrosine kinase of Bcr ± Abl. Our studies show that Jak2 is tyrosine-phosphorylated in several hematopoietic cell lines that express Bcr-Abl. However, three Bcr ± Abl negative cell line controls (HL60 and Mo7e and 32D shown in Figure 1 ) did not have detectable levels of tyrosine-phosphorylated Jak2. Of interest, Jak2 was tyrosine phosphorylated in cells from blast crisis CML patients but not in cells from a healthy individual (Figure 1 ). Similar to that shown previously with Jak1 and the v-Abl protein (Danial et al., 1998) , the C-terminus of Bcr ± Abl binds ®rmly to Jak2 (Figures 4 and 5 ). Other regions of P210 BCR ± ABL do not contribute to complex formation in any signi®cant way. Moreover, the kinase activity of Bcr ± Abl does not seem to be involved in complex formation, as complex formation is maintained at levels of STI-571 that almost completely block Bcr ± Abl tyrosine kinase activity. It is well known that the SH2 domains of the nonreceptor tyrosine kinases play an important role in target selection (Songyang et al., 1995) . We examined the SH2 deletion mutant of P210 BCR ± ABL for its ability to phosphorylate Jak2 in 32D cells stably transfected with either wild-type or the SH2 deletion mutant form of the BCR ± ABL gene. The SH2 deletion mutant was defective in its ability to induce phosphorylation of the endogenous Jak2 protein whereas the SH3 deletion mutant of Bcr ± Abl was only partially defective (Figure 2 ). Thus although Jak2/ Bcr ± Abl complex formation requires the C-terminus of Abl, optimal phosphorylation of Jak2 by Bcr ± Abl requires the SH2 domain.
We also examined the tyrosine residues in Jak2 that were phosphorylated by Bcr ± Abl. Tyrosine 1007 but not tyrosine 1008 was the preferred site of phosphorylation by either the recombinant 45 kDa c-Abl protein (containing only the SH2 domain and the catalytic domain) or Bcr ± Abl (Figure 6a ). Moreover, a phosphotyrosine 1007 sequence-speci®c antibody speci®cally detected Jak2 in cells expressing P210 BCR ± ABL (Figure 6b) .
We tested the ability of a kinase-inactive Jak2 protein to block the oncogenic activity of K562 cells. Importantly, colony formation in soft agar was greatly inhibited compared to vector transfected K562 cells (Figure 7a) . Also, tumor formation of K562 cells in nude mice was similarly inhibited by kinase-inactive Jak2 (Figure 7b ). These results provide convincing evidence that Jak2 plays an important role in the oncogenic eects of Bcr ± Abl.
Of importance, we found that uncultured blood cells from blast crisis CML patients but not normal marrow cells contained tyrosine phosphorylated Jak2 ( Figure  1 ). These results are signi®cant, as they indicate that the activation of Jak2 might well be important in CML pathology in the blast crisis stage.
Although we have readily detected complexes between Jak2 and Bcr ± Abl (Figures 2 ± 5) , others have failed to detect these complexes (Ilaria and Van Etten, 1996) . Although we cannot explain their negative results, we found that the source and type of Jak2 antibody reagent was important (e.g. use of a Jak2 antibody conjugated to agarose beads). Using this antibody, we demonstrated the presence Jak2/Bcr ± Abl complexes not only in co-transfected COS1 cell, (Figure 4 ) but also in 32D cells expressing P210 BCR ± ABL (Figure 3) .
It remains to be determined what signal transduction pathways are aected by an activated Jak2 in CML cells. We did not ®nd any changes in Stat5 protein tyrosine phosphorylation in kinase-inactive JAK2 expressing K562 cells compared to vector control (Figure 8) . Moreover, Stat5 immune complexes from P210 BCR ± ABL expressing 32D cells lacked Jak2 (S Xie and R Arlinghaus, unpublished data). However, it is important to emphasize that Jak2, although known for its involvement in the Jak/Stat pathway, has been shown to be involved in other signal transduction pathways. For example, Jak2 kinases are directly implicated in the activation of the kinase Pyk2 (Miyazaki et al., 1998) , stimulation of the Ras/MAPK pathway (Barge et al., 1996) , and the induction of the c-FOS and c-MYC genes (Watanabe et al., 1997) . Of interest, transformation of myeloid leukemia cells to cytokine independence by Bcr ± Abl involves kinaseactive Hck, a Src family member (Lionberger et al., 2000) . Importantly, like the Abl/Jak2 interaction, the Hck kinase also binds tightly to the C-terminus of Abl. Besides competition with endogenous Jak2, it is possible that kinase-inactive Jak2 may also compete with Hck for binding to Bcr-Abl. Studies are underway to determine whether Src kinase pathways and/or other pathways are aected by kinase-inactive Jak2. Figure 8 Stat5 tyrosine phosphorylation is not reduced in K562 cell clones expressing kinase-inactive Jak2. K562 cell clones, which were transfected with kinase-inactive Jak2 plasmid, were selected for growth in G418 (neo resistance). Cells were lysed, immunoprecipitated with anti-Stat5, and Western blotted with either anti-phosphotyrosine (4G10) (a) or with anti-Stat5 (b). Clones K1-4 and K1-8 had reduced growth in colony and nude mouse assays (shown in Figure 7 )
Materials and methods

Plasmid constructs
The JAK2 (wt) or JAK2 (K/E) inserts were released from pBSK(+)/JAK2 (wt) or prk5/JAK2 (K/E) (provided by Dr James Ihle, St. Jude Children's Hospital, Memphis, TN, USA) by NotI and EcoRV double digestion, and then JAK2 (wt) or JAK2 (K/E) were subcloned into pcDNA3d(7)/neo vector (Invitrogen Corporation, Carlsbad, CA, USA). BCR1-63-ABL/DNar and BCR1-63-ABL/Nar-End were released from pSLX/BCR1-63-ABL/DNar and pSLX/BCR1-63-ABL/ Nar-End (provided by Dr Jean YJ Wang, University of California at San Diego, La Jolla, CA, USA) by BamHI digestion and then BCR1-63-AbL/DNar or BCR1-63-AbL/ Nar-End were subcloned into pcDNA3.1(7)/neo vector.
Tissue cultures
32D pSRaMSVtkneo vector, 32D pSRaMSVtkneoP210, 32D pSRaMSVtkneop210DSH2 and 32DpSRaMSVtkneo p210DSH3 cells were provided by Dr Tomasz Skorski (Temple University, Philadelphia, PA, USA). 32D pSRaMSVtkneo vector and 32DpSRaMSVtkneo p210 DSH2 cells were cultured in DMEM with 10% FCS plus 10% WEHI medium. 32DpSRaMSVtkneo p210 and 32D pSRaMSVtkneop210DSH3 cells were cultured in DMEM with 10% FCS. HL-60p185 BCR ± ABL cells were provided by Dr Douglas Green (La Jolla Institute for Allergy and Immunology, La Jolla, CA, USA). HL-60p185 BCR ± ABL and HL-60 cells were cultured in RPMI-1640 with 10% FCS. Mo7e cells (Sirard et al., 1994) were cultured in DMEM with 10% FCS plus 10 U/ml human IL-3. M3.16 cells were cultured in DMEM with 10% FCS (Sirard et al., 1994; Wilson-Rawls et al., 1996) . K562 and B15 cells were cultured in RPMI-1640 with 10% FCS. For cells treated with Abl kinase inhibitor STI-571 (Novartis Pharmaceuticals, East Hanover, NJ, USA), variable concentrations of STI-571 were added to the culture medium for 3 h before harvesting the cells for further assay. COS1 cells were cultured in DMEM with 10% FCS.
Antibodies
Anti-Jak2 antibodies, SC-278 and SC-294AC (as an antibody/agarose conjugate), were purchased from Santa Cruz Biotechnology, Inc (Santa Cruz, CA, USA). Anti-phosphotyrosine antibody, 4G10, was purchased from Upstate Biotechnology Inc. (Lake Placid, NY, USA). Anti-Stat5 (SC-835) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). It recognizes both Stat5a and 5b. Anti-Abl 8E9 monoclonal antibody , antiBcr(1 ± 16), and p6D monoclonal anti-Abl(51 ± 64) were produced by our own laboratory (Liu et al., 1993) . Antiphosphotyrosine 1007 sequence speci®c Jak2 polyclonal antibody was made by Bethyl Laboratories, Inc. (Montgomery, TX, USA). The immunogen sequence was CPQDKEpYYKVKEPGE.
Immunoprecipitations and Western blot
Two 610 7 cells from various cell lines were lysed on ice in Guo lysis buer containing Trasylol (100 KIU/ml) (Miles Inc., Kankakee, IL, USA), sodium vanadate (0.2 mM) and 0.1 mg/ml protease inhibitor, 4 (2-aminoethyl) benzenesulfonyl¯uoride hydrochloride (AEBSF) (Sigma Chemical Co., St. Louis, MO, USA), for 20 min and then centrifuged at 14 000 r.p.m. (16 000 g) for 20 min at 48C. The supernatant¯uids were used for immunoprecipitation as follows. For Jak2 immunoprecipitation, 25 ml of antiJak2 antibody agarose conjugate, SC-294AC (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to 500 ml of lysate. The immune complexes were incubated at 48C for 2 h with rotation. For Stat5 immunoprecipitation, 15 ml antiStat5 antibody, SC-835 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to 500 ml of lysate. The immune complexes were incubated at 48C with rotation. Two hours later, 40 ml protein A/G PLUS-Agarose, SC-2003 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was added to the mixtures and incubated for another hour with rotation at 48C. In each case the agarose beads were collected by centrifugation at 14 000 r.p.m. (16 000 g) for 1 min in an Eppendorf centrifuge at 48C and followed by re-suspension in 1 ml lysis buer. This wash process was repeated three times and ®nally the collected agarose beads were boiled in 40 ml of SDS sample buer for 5 min. Proteins were resolved on 8% SDS ± PAGE and transferred to Immobilon TM membrane (Millipore Co., Bedford, MA, USA). The transferred membranes were used for Western blotting with various antibodies. The antibodies used for Western blotting are summarized as follows: anti-phosphotyrosine 4G10 (1 : 4000), anti-Jak2 SC-278 (1 : 200), anti-Stat5 SC-835 (1 : 1000), antiAbl 8E9 (1 : 1000), anti-Bcr G143 (1 : 1000).
Blood samples from CML blast crisis patients were incubated with LR buer for 10 min and then centrifuged to obtain the pellets. The pellets were washed once with LR buer, and then the pellets incubated in PBS with 0.1 mg/ml protease inhibitor AEBSF for 20 min. Mononuclear cells from normal bone marrow donor were separated by HISTOPAQUE 1 -1077 (Sigma Diagnostics, Inc., St. Louis, MO, USA). The pellets were used for immunoprecipitation/Western blotting as above.
Kinase assay
The wild-type or Y-to-F mutant peptides corresponding to Jak2 activation loop were synthesized by our core laboratory. These peptides were incubated with commercial Abl kinase (New England Biolabs, Beverly, MA, USA) or the immunoprecipitated Bcr ± Abl kinase from K562 cells in their respective kinase assays. Peptides phosphorylation was visualized by autoradiography of SDS ± PAGE fractionated peptides. The peptide sequence is: 994-DFGLTKVLPQKE Y 1007 Y 1008 KVKEPGESPIF-1019.
Transfection
For COS1 transfection, 3 mg pcDNA3.1 (7)/JAK2 and 3 mg pcDNA3.1 (7)/BCR1-63-ABL/DNar or 3 mg pcDNA3.1 (7)/BCR1-63-ABL/Nar-End were co-transfected into 60 mm dish COS-1 cells with 10 ml LipofectAMINE (Life Technologies, Rockville, MD, USA). For K562 cells transfection, 2 mg pcDNA 3.1(7)/neo/JAK2 (K/E) or 2 mg pcDNA3.1(7)/neo vector control DNA were transfected into 35 mm dish K562 cells with 10 ml DMRIE-C TM Reagent (Life Technologies, Rockville, MD, USA). The transfected K562 cells were selected on soft-agar with 400 mg/ml G418 (Wu et al., 1999) .
GST ± Abl pull-down assays
Various GST ± Abl protein fragments were constructed as described (Lionberger et al., 2000) . The JAK2 cDNA was provided by Dr Richard Jove (Mot Cancer Center, University of South Florida, Tampa, FL, USA). The 5' end was modi®ed by PCR to remove untranslated sequences, which were replaced with a consensus Kozak sequence and restriction site to allow subcloning into the baculovirus transfer vector pVL1392. The recombinant baculovirus was created by co-transfecting Sf-9 cells with the transfer vector and Baculogold viral DNA according to manufacturer's instructions (BD-PharMingen, San Diego, CA, USA). Cell lysates of Sf9 cells co-expressing Jak2 and each of GST ± Abl constructs were precipitated with glutathione-agarose (GSH-agarose) beads in standard pull-down assays (Lionberger et al., 2000) . Bound proteins were solubilized by SDS ± PAGE sample buer, and the associated Jak2 protein was detected by immunoblotting with anti-Jak2 (SC-278).
Colony assay
Five hundred K562/vector control cells or K562DN/Jak2 cells were seeded in soft agar for colony formation assay . Colonies were counted 2 weeks later.
Nude mice tumor assay
Ten million K562/DN Jak2 or K562/vector control cells were subcutaneously injected to 6-week old female nude mice. Each mouse had four dierent injection sites on its back. Each group had ®ve mice.
